We Are Leading Microbiome and Probiotics Research Forward
We collaborate with leading research institutions, universities, Key Opinion Leaders (KOLs), and industry experts, engaging in scientific and regulatory discussions to push the boundaries of microbiome science and translational discoveries. Our key positions in renowned associations include the European Microbiome Innovation for Health (EMIH, formerly known as Alliance Promotion Microbiome-APM), the Human Microbiome Action Project (HMA), Ferments du Futur , The Harmi initiative , and the French Gut project.
Microbiota sampling is now systematically included in every clinical study to better understand host-microbe interactions. Our in-house research lab team has developed and standardized a microbiome analysis pipeline. This pipeline covers the acquisition and processing of various sample types, accounting for several human microbiotas: fecal (including meconium), vaginal, oral, skin, and breastmilk (including colostrum). Sample metadata collection, along with sequencing data and bioinformatics analysis, provides qualitative details on the microbiota ecology at different sites in the human body and key insights into microbial metabolic interactions through the integration of multi-omics approaches
Exploring New Frontiers in Microbiome Science
Advancing microbiome science also raises the challenging question: “Can we go even further in this exploration inside us?” This applies to the small intestine, an uncharted territory home to specific bacteria, which constitutes a dynamic environment that differs from the colon and likely plays important roles beyond digestion. These intriguing questions — How do different small intestine microbes modulate gastrointestinal function, and how can probiotics play a role in this niche? — led us to develop an exciting collaboration with Nimble Science. We used an innovative sampling method called the Small Intestine MicroBiome Aspiration (SIMBATM) capsule for convenient, non-invasive, high-quality, and reliable sampling to study diet-microbiota interactions in the small intestine. With Nimble Science, we published a proof-of-concept clinical study validating the efficacy of the capsule to detect probiotic strain interventions in the small intestine, which was not possible using conventional stool samples. This high-accuracy capsule is now recognized as a Class II medical device in Canada and will undoubtedly become an invaluable research tool in clinical trials for studying probiotic microbiota interactions in health and disease, and perhaps eventually for the clinical diagnosis of gastrointestinal tract conditions affecting the small intestine, such as Small Intestinal Bacterial Overgrowth (SIBO).
Developing Next-Generation Probiotics
Our innovative microbiome program also focuses on developing next-generation probiotics (NGPs) and improving industrial capabilities. Supported by an integrated and translational research platform spanning from research models to clinical studies and bioprocess development, our in-house research team now specializes in over 15 next-generation species, with some candidates integrated into the discovery pipeline. Our commitment extends to overcoming well-known bottlenecks, particularly with strict anaerobes sensitive to oxygen exposure and with specific nutrient needs.
Building on our founders’ legacy, we are expanding the therapeutic potential of probiotics across multiple health indications. By developing innovative, integrated approaches that combine novel candidate strains with advanced experimental tools, we aim to uncover new mechanistic insights."